Subscribe to our Newsletters !!
Although copying the blueprint is extremely comple
Eppendorf introduces a new addition to their Eppen
The recent rabies death of an 11 year old Canadian
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to the latest issue of Micro
Effective antivirals with secure clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients using COVID-19, the authors discovered that hypercoagulability according to elevated levels of D-dimers was associated with illness severity.
By calculating of a U.S. FDA approved drug library, the authors identified that an anticoagulation agent dipyridamole (DIP) at silico, which suppressed SARS-CoV-2 replication invitro.
At a proof-of-concept trial between 31 patients using COVID-19, DIP supplementation has been associated with significantly decreased concentrations of D-dimers (P<0.05), greater lymphocyte and platelet recovery in the flow, and markedly enhanced clinical outcomes for the severely ill patients compared with the control patients.
To sum up, DIP could be used for the treatment of seriously ill patients using COVID-19 through antibacterial and anticoagulation consequences.
Ascension Parish School Board
Liu, X., et al. (2020) Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Elsevier. doi.org/10.1016/j.apsb.2020.04.008.
